Drug intelligence / Profile preview

RapMed-2003

Development stage: Unknown
Lead developer: RAPHAS
Modality: Hydrogel Systems → Drug Delivery Systems, Peptides, Small Molecules
Administration: Transdermal

Overview

RapMed-2003 is a GLP-1 receptor agonist delivered via a dissolving microneedle patch, currently under development by RAPHAS for the treatment of type 2 diabetes and obesity. The product utilizes a semaglutide analog formulated into RAPHAS's proprietary microneedle technology, which allows for transdermal delivery of the medication as an alternative to subcutaneous injections. A Phase 1 clinical trial in 30 subjects was completed in late 2024, evaluating the safety, tolerability, and pharmacokinetic profile of the patch formulation.

Other names: Semaglutide analog

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on RapMed-2003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RapMed-2003.

Explore the full profile